Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase.

Bao X, Kobayashi M, Hatakeyama S, Angata K, Gullberg D, Nakayama J, Fukuda MN, Fukuda M.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12109-14. doi: 10.1073/pnas.0904515106. Epub 2009 Jul 8.

2.

Mdm2-mediated ubiquitylation: p53 and beyond.

Marine JC, Lozano G.

Cell Death Differ. 2010 Jan;17(1):93-102. doi: 10.1038/cdd.2009.68. Review.

3.

Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE.

de Bernabé DB, Inamori K, Yoshida-Moriguchi T, Weydert CJ, Harper HA, Willer T, Henry MD, Campbell KP.

J Biol Chem. 2009 Apr 24;284(17):11279-84. doi: 10.1074/jbc.C900007200. Epub 2009 Feb 24.

4.

Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.

Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM.

Cancer Res. 2008 Dec 1;68(23):9583-8. doi: 10.1158/0008-5472.CAN-07-6178.

5.

Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.

Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D, Somers GR.

Pediatr Dev Pathol. 2009 Mar-Apr;12(2):127-35. doi: 10.2350/08-05-0477.1. Epub 2008 Sep 12.

PMID:
18788888
6.

Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations.

Ren YX, Finckenstein FG, Abdueva DA, Shahbazian V, Chung B, Weinberg KI, Triche TJ, Shimada H, Anderson MJ.

Cancer Res. 2008 Aug 15;68(16):6587-97. doi: 10.1158/0008-5472.CAN-08-0859.

7.

PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma.

Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, Abboud HE, Legallo RD, Qualman SJ, Rubin BP, Keller C.

Oncogene. 2008 Nov 20;27(51):6550-60. doi: 10.1038/onc.2008.255. Epub 2008 Aug 4.

8.

Genetic modeling of Ras-induced human rhabdomyosarcoma.

Linardic CM, Counter CM.

Methods Enzymol. 2008;438:419-27. doi: 10.1016/S0076-6879(07)38028-2.

9.

PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.

Cen L, Hsieh FC, Lin HJ, Chen CS, Qualman SJ, Lin J.

Br J Cancer. 2007 Sep 17;97(6):785-91.

10.

Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors.

Martin LT, Glass M, Dosunmu E, Martin PT.

Hum Pathol. 2007 Nov;38(11):1657-68. Epub 2007 Jul 19.

11.

Hedgehog-independent overexpression of transforming growth factor-beta1 in rhabdomyosarcoma of Patched1 mutant mice.

EichenmĂĽller M, Bauer R, Von Schweinitz D, Hahn H, Kappler R.

Int J Oncol. 2007 Aug;31(2):405-12.

PMID:
17611698
12.

Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells.

Chen CL, Loy A, Cen L, Chan C, Hsieh FC, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K, Lin J.

BMC Cancer. 2007 Jun 28;7:111.

13.
14.

Effects of RAS on the genesis of embryonal rhabdomyosarcoma.

Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X, Goessling W, Neuberg DS, Kunkel LM, Zon LI.

Genes Dev. 2007 Jun 1;21(11):1382-95. Epub 2007 May 17.

15.

Loss of suppressor-of-fused function promotes tumorigenesis.

Lee Y, Kawagoe R, Sasai K, Li Y, Russell HR, Curran T, McKinnon PJ.

Oncogene. 2007 Sep 27;26(44):6442-7. Epub 2007 Apr 23.

PMID:
17452975
16.

N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution.

Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD, Kozutsumi Y, Suzuki A, Wynshaw-Boris A, Ryan AF, Gallo RL, Varki N, Varki A.

Mol Cell Biol. 2007 Jun;27(12):4340-6. Epub 2007 Apr 9.

17.

Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with beta-dystroglycan.

Rezniczek GA, Konieczny P, Nikolic B, Reipert S, Schneller D, Abrahamsberg C, Davies KE, Winder SJ, Wiche G.

J Cell Biol. 2007 Mar 26;176(7):965-77.

18.

Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma.

Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA.

FASEB J. 2007 Jul;21(9):2195-204. Epub 2007 Mar 14.

PMID:
17360850
19.

PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN.

Li HG, Wang Q, Li HM, Kumar S, Parker C, Slevin M, Kumar P.

Cancer Lett. 2007 Aug 18;253(2):215-23. Epub 2007 Mar 9.

PMID:
17350164
20.

Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas.

Wysoczynski M, Miekus K, Jankowski K, Wanzeck J, Bertolone S, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ.

Cancer Res. 2007 Mar 1;67(5):2131-40.

Supplemental Content

Support Center